FDA Approves Xermelo for Carcinoid Syndrome Diarrhea
February 28, 2017
February 28, 2017
WASHINGTON, Feb. 28 -- The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:
The U.S. Food and Drug Administration today approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled.
Carcinoid syndrome is a cluster of symptoms sometimes seen in people with car . . .
The U.S. Food and Drug Administration today approved Xermelo (telotristat ethyl) tablets in combination with somatostatin analog (SSA) therapy for the treatment of adults with carcinoid syndrome diarrhea that SSA therapy alone has inadequately controlled.
Carcinoid syndrome is a cluster of symptoms sometimes seen in people with car . . .